IL6 and thrombocytosis disease: Recent clinical trials and living meta-analyses in hyperinflammatory conditions confirm that IL-6 blockade is safe and modulates key inflammatory readouts, supporting translational exploration in cytokine-driven thrombocytosis [24,82].